Fig. 1.

Labeling of apoA-I-V53C variant by POLARIC-maleimide. A: Effect of POLARIC-labeling on ABCA1-dependent cholesterol efflux. BHK/ABCA1 cells were treated with (filled bars) or without (open bars) 10 nM mifepristone for 20 h and incubated with indicated acceptors (5 μg/ml) for 6 h. Cholesterol content in the medium was determined using a fluorescence enzyme assay. B: Fluorescence emission spectra of apoA-I-POLARIC in the lipid-free state (dotted line) or dHDL particles (solid line). Protein concentrations were 5 μg/ml.